BioSpace News Archive

DURECT Corporation announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis, as well as information on DURECT’ investigational drug candidate, DUR-928, being developed for the treatment of AH.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced that data from the 24-hour open-label portion of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) Study will be presented during the American Heart Association (AHA) Scientific Sessions 2020

EV Biologics Corp (OTC PINK:YECO) today announced that it has completed all its filings on OTC Markets and is now current in its reporting showing a Yield sign. The Company targeted to become current in its reporting before the end of October and is pleased to have achieved its goal within the announced time frame. Being current now allows the majority of brokers to trade in our shares, whereas before only online brokers could buy or sell the sec

Ascendum Solutions, a global digital innovation firm, today announced the product release of SafeReturnTM, a mobile application designed to help limit the spread of COVID-19 and comply with New Jersey Executive Order No. 192 to protect worker safety.

Imagin Medical Inc. announced that further to its press release of October 22, 2020, it has closed the first US$750,000 tranche of a proposed offering of up to US$3 million aggregate principle amount Convertible Notes.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a research collaboration with Thomas Jefferson University and the Sidney Kimmel Cancer Center – Jefferson Health for a study from the window of opportunity trial of Nivolumab and Tadalafil for patients with squamous cell carcinoma of the head and neck.

Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis today announced that it has enrolled the last patient in the 75 mg CRV431 cohort of its Phase 2a

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, will host a conference call for the investment community to pose questions related to the Company’s third quarter 2020 financial and operating results. The call will be held because of technical issues experienced by the Company’s external conference call host during the earnings call that took place on Novemb

Mino-Lok, Company’s lead product, is progressing through Phase 3 trials and to be positioned for market entry into an estimated $1.5 billion market